Articles tagged with Effector Cells
Researchers at La Jolla Institute for Immunology discovered that immune cells in lung tissue express genes associated with autoimmune disease risk. These tissue-resident immune cells may actively drive the development of autoimmune diseases, particularly in women.
A recent study found that human lung tissue contains a vast reservoir of tissue-resident memory T cells (T RM cells) capable of targeting a range of viruses, bacteria, and fungi. These cells reside only in the lungs and can live for years, providing a vital line of defense against severe respiratory infections.
Scientists at La Jolla Institute for Immunology have discovered that 'cross-reactive' T cells can recognize multiple species of paramyxovirus, including measles and Nipah viruses. This broad protection is essential in combating emerging diseases with unknown viral strains.
Researchers at La Jolla Institute for Immunology have discovered that combining key vaccine ingredients could give the body the tools it needs to fight the entire family of arenaviruses with a single vaccine. This approach may protect against life-threatening infections from Lassa virus, Junin virus, and many other arenaviruses.
Researchers at La Jolla Institute for Immunology discovered that FluMist can trigger an immune response directly in nasal tissue, training immune cells to recognize and fight influenza virus infection. This response stays in the upper airways and cannot be detected via blood samples.
Researchers reveal that immune system's T cells travel to the prostate to provide long-term protection against infections. Harnessing these disease-fighting cells could lead to new therapies for prostate cancer and inflammatory conditions.
Researchers redesigned a key component of lipid nanoparticles to steer particles toward lymph nodes, reducing off-target delivery. This advancement could make mRNA vaccines more efficient, potentially achieving strong immune protection at lower doses.
Researchers at the Wyss Institute developed DoriVac, a DNA nanotechnology-enabled vaccine platform that induces broad immunity against infectious viruses, including SARS-CoV-2, HIV, and Ebola. The platform produces potent antigen-specific immune responses and is more stable and easier to manufacture than traditional vaccine platforms.
Researchers at La Jolla Institute for Immunology discovered that ALS is likely caused by an autoimmune reaction triggered by inflammatory CD4+ T cells targeting specific proteins in the nervous system. Anti-inflammatory CD4+ T cells may slow disease progression and prolong survival times.
Researchers discovered that immune cells called T cells are abundant in mammary glands during pregnancy and breastfeeding, with some relocating from the gut. This finding may help explain the benefits of breastfeeding and inform dietary decisions to enhance breast milk production and quality.
Researchers have identified a key player in the development of Fusarium head blight, a devastating disease that severely damages wheat and barley crops worldwide. The discovery of FgTPP1 could lead to the development of genetically engineered disease-resistant grains.
Researchers at La Jolla Institute for Immunology discovered that CD4+ T cells target Chikungunya virus, leading to chronic inflammation and joint pain. The study suggests that these monofunctional T cells may be the culprits behind arthritis-like symptoms in CHIKV patients.
A study co-authored by an Iowa State University professor identified a single protein that triggers chemical signals called effectors in cyst nematodes, which hijack plant cells. Disrupting this protein could severely reduce nematode infections, making it a powerful method for reducing crop damage.
Scientists at Goethe University Frankfurt have discovered a new way to tailor natural killer cells to target leukemia cells, improving their efficacy. The researchers used CRISPR/Cas9 gene editing to disable an immune checkpoint, allowing the modified cells to attack cancer cells more effectively.
A team of researchers has discovered a mechanism by which the liver's immune cells are suppressed in chronic hepatitis B, leading to organ damage. The 'sleep timer' function allows immune cells to weaken their activity over time, preventing them from proliferating excessively and causing further damage.
Researchers at TUM have uncovered a mechanism by which tumor cells prevent the formation of immune responses, including cytotoxic T cells. This discovery provides rationales for new cancer immunotherapies and could enhance existing treatments.
Researchers at the University of Toronto and Sinai Health have created a new platform to identify proteins that can be co-opted to control the stability of other proteins. The study identified over 600 new effector proteins that could be used therapeutically, including those that can efficiently degrade or stabilize target proteins.
A team of researchers from Okayama University found that short-chain fatty acids produced by intestinal bacteria trigger elongation of dendrites in dendritic cells, capturing intestinal pathogens and enhancing immune responses. This discovery may lead to the development of new treatments targeting dendritic cells to prevent diseases.
A new subset of memory B cells, marked by the FcRL5 receptor protein, has been identified as a predictor of long-lived antibody responses to influenza vaccination. These effector memory B cells can be detected seven days after immunization and correlate with vaccine antibody responses months later.
A new Northwestern University study suggests that COVID-19 boosters may be less effective due to pre-existing antibodies from initial vaccinations. The study found that these antibodies can rapidly clear the booster from the body, limiting its efficacy. Increasing time between vaccinations is also beneficial for the immune response.
Researchers investigated the effects of everolimus on the STAT3/HIF-1α/VEGF pathway in TP53 mutant cell lines and xenograft models. Everolimus treatment significantly inhibited cell growth and reduced tumor angiogenesis and lymphangiogenesis.
Researchers found that clearance of p16Ink4a-positive cells did not impact β-cell mass, but improved β-cell function and proliferative capacity in a subset of HFD mice. The targeted subpopulation of β-cells is non-proliferative and non-SASP producing.
A study characterizes secreted proteins from Candidatus Liberibacter solanacearum, a newly emerging pathogen of tomato and potato. The proteins, called effectors, offer clues into the manipulation tactics used by the bacterium to subdue its plant host.
A recent study published in Developmental Cell reveals that Kras mutation causes chromatin rearrangement, leading to stem-like cell regeneration and tumor onset. The team discovered a protein complex called AP-1 as the mediator of this process, which can be targeted with small-molecule drugs.
Researchers at UTA have discovered commonalities among caspases 3, 6, and 7 that could allow for the isolated activation of proteins in tumor cells without disrupting healthy cells. By understanding how effector caspases work in healthy conditions, they hope to develop methods to destroy abnormal cells while preserving healthy ones.
Researchers discover tBID can induce programmed cell death through mitochondrial damage, revealing a new function for a previously thought signal transducer protein. This finding has implications for treating malignant cells and combating infections like Shigella.
Researchers at the University of Würzburg have found that innate lymphoid cells can specialize into killer cells that recognize and kill tumour cells. The study reveals a new transcription factor, Hobit, drives this specialization process.
Researchers characterize Photorhabdus Virulence Cassette as potent effector Pdp1, responsible for cytotoxicity against eukaryotic cells. The cassette enables direct translocation of effectors into mammalian macrophages to induce cell death.
Research found that activating plasmacytoid dendritic cells with interferon-beta increases CD40 expression and induces CD38 upregulation on AML cells, leading to antibody-mediated killing. This mechanism may provide a novel therapeutic approach for acute myeloid leukemia.
A new AI platform has identified specific proteins that allow bacteria to infect the intestines, paving the way for smart drugs to prevent disease. The study used machine-learning tools and genomic information of multiple bacteria to make accurate predictions.
A team of scientists has developed an AI model that can predict the success of bacterial infections by analyzing the interactions between different effectors. The study found that even if some effectors are removed, the infection can still take hold due to the inherent strength and flexibility of the effector network.
Stanford researchers developed a novel technique attaching nanobodies to CRISPR for targeted gene control. This combo enables precise on/off switching of specific genes, potentially correcting epigenetic defects without combining large effectors.
A new study reveals that antibody effector functions are crucial for effectively treating COVID-19 infections, but dispensable when preventing infection. Researchers found that optimized effector functions can boost the potency of next-generation COVID-19 antibody drugs, while removing them may hinder treatment effectiveness.
The study reveals that N-terminal amphipathic motifs of certain Arf proteins determine their specific subcellular localization in a GTP-independent manner. This uncoupling of membrane association and activation may provide new insights for targeting proteins to specific intracellular locations.
Researchers discovered Shigella's molecular strategy to disarm host cell protective mechanisms, including apoptosis and necroptosis. By blocking apoptosis with OspD3 and activating necroptosis with OspC1, Shigella ensures its survival and proliferation.
Researchers have developed light-activated tools to influence lipid concentration in living cells, shedding light on the 'lipid code'. This approach could enable medical professionals and biochemists to verify results with quantitative data from living cells.
Scientists are searching for the source of group E antibodies, which trigger most allergic reactions. They aim to deepen understanding of these molecules and develop effective treatments, as class E immunoglobulin is involved in one-third of all diseases.
Researchers at UT Southwestern Medical Center found that Vibrio parahaemolyticus bacteria deploy a needle-like apparatus called Type III Secretion System (T3SS) to inject toxic proteins into cells, disabling their ability to produce defensive molecules like reactive oxygen species. This allows the bacteria to escape the gut and cause l...
Scientists at Virginia Tech Carilion Research Institute have found a way to influence long-term memory formation in the immune system. The researchers discovered that proteins responding to the cells' environment can push effector cells towards memory, leading to the creation of specialized cells to combat specific invading pathogens.
A recent study published in Nature Immunology revealed that the body suppresses long-lived lymphoid cells to prevent excessive inflammation. Cytokine chemicals like interferon-beta, gamma and interleukin-27 can shut off these cells, allowing for a targeted immune response.
Researchers at EPFL have discovered how a major effector protein regulates gene expression by speeding up its search for chromatin binding sites. By increasing its binding rate and forming dimers to maximize interaction with chromatin, HP1α enhances gene regulation efficiency.
Researchers have discovered a molecule, IGF-1, that can induce the production of T-reg cells, suppressing symptoms of autoimmune diseases. The findings confirm IGF-1's direct action on T-reg cells, making it a promising therapeutic option for conditions like type-1 diabetes and multiple sclerosis.
Scientists identified a broadly neutralizing HIV-1 antibody in a lupus patient, which could be used to target rapidly mutating viruses. Researchers also developed a workflow to evaluate protein turnover kinetics, revealing previously unknown alterations in disease development.
A UC Riverside team discovered a novel 'virulence mechanism' of Botrytis cinerea, a fungal pathogen that can infect over 200 plant species. The pathogen delivers RNA effectors into host cells to suppress immunity and cause infection.
Researchers at Tufts University School of Medicine identified how Yersinia bacteria immobilizes the immune system to grow in infected organs. The study used a TEM-1 reporter system to color-code cells and found that YopH deactivates multiple proteins, blocking calcium flows vital to normal immune cell communication.
A team of researchers at the University of California, Riverside, has discovered a genetic mechanism that explains how Phytophthora pathogens compromised the potato plant's immune system during the Irish Famine. The study reveals that RNA silencing pathways are suppressed by effectors, leading to an increase in susceptibility to disease.
New research reveals the molecular basis of a bacterial effector protein called Cif, which manipulates host cell processes for infection and colonisation. The study identifies the structure of Cif bound to its target NEDD8, providing insights into pathogenesis and potential new tools for probing cellular functions.
Loyola researchers found a molecule called transforming growth factor beta (TGF-β) that can amplify the immune response in some cases and suppress it in others. This discovery could lead to the development of new drugs to regulate the immune system, such as activating it to attack tumor cells or suppressing it to prevent organ rejection.
New research at the Weizmann Institute shows how blood vessel cells 'hide' signals from immune cells, only allowing those with special training to cross. This selective barrier prevents certain immune cells from reaching tumors near blood vessels.
Researchers at Iowa State University have developed a new type of hybrid protein that can make precise double-strand DNA breaks in living cells. This breakthrough could lead to more efficient gene replacement and editing therapies, enabling modifications to plant, animal, and human genomes.
A research team at Virginia Tech has discovered a fundamental entry mechanism for fungal microbes to infect plants and cause disease. Special disease-related proteins, known as effectors, bind to a specific lipid molecule found on the cell surface before entering the cell.
A team of researchers has identified XIAP as the critical factor determining which cell death pathway is followed to culminate in a cell's death. This finding has implications for cancer patients with underlying liver conditions who are being treated with IAP inhibitors.
Transplanting human umbilical cord blood cells into mouse models with ALS delayed disease symptom progression and increased lifespan. The moderate-strength dose of HUCB cells proved most effective in providing neuroprotection for motor neurons.
Xencor's engineered antibody Fc variants show enhanced effector functions, killing tumor cells 10 times more toxic than conventional treatments. These advancements hold promise for developing next-generation antibody therapeutics.
Researchers at Cold Spring Harbor Laboratory investigate the concept of return to normalcy in genetic systems. They uncover new insights into how cells can re-establish normal gene expression after perturbations.
Researchers found that human cells use RalGEFs as primary effectors of Ras-mediated tumorigenesis, unlike in rodents. This discovery highlights the need for caution in using mice to model human disease and opens new avenues for cancer therapy targeting.